Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC).

Authors

• William Kelly

Publication/Presentation Date

5-2020

Volume

38

Issue

15

Published In/Presented At

DOI: 10.1200/JCO.2020.38.15_suppl.5573

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article